GLP-1-Based Therapeutics Summit

Welcome to the Inaugural GLP-1-Based Therapeutics Summit! - Elucidate Strategies for Product Specialization and Indication Expansion through Pharmacoeconomic Analysis

Grab your copy of the Full Agenda: https://ter.li/jphri4

Amidst the resounding success of Novo's SELECT trial, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments. Each passing week witnesses the unveiling of new multi-million-dollar investments, propelling GLP-1 players to the forefront of pharmaceutical revenue growth.

Uniting the industry decision-makers behind the explosion of GLP-1 assets, the GLP-1-Based Therapeutics Summit stands as a pivotal platform. Uniquely positioned, it serves as the nexus for industry decision-makers, providing invaluable insights to guide therapeutic strategies, enabling the development of the right drugs for patients at the right price.

Built with insights from industry giants including Eli Lilly, Novo Nordisk, Amgen, Carmot Therapeutics, Altimmune, and Pfizer, join 80+ industry leaders in Product Planning, Clinical Development, Medical Research, and Commercial Strategy.

If you are looking to differentiate your GLP-1 products, stand out in the market, or discover the newest innovations in improving tolerability, efficacy, and durability of GLP-1s, there has never been a more appropriate time to unite and navigate this exploding field!

Register now for exclusive savings and additional group discounts: https://ter.li/b5fj5s

URLs:
Website: https://go.evvnt.com/2215794-0?pid=10018
Tickets: https://go.evvnt.com/2215794-2?pid=10018
Brochure: https://go.evvnt.com/2215794-3?pid=10018

Prices:
Drug Developer Pricing | Conference Only: USD 2999.00,
Academic Pricing | Conference Only : USD 2599.00,
Standard Pricing | Conference Only: USD 3699.00

Speakers: Andrew Young - Chief Medical Officer - i2o Therapeutics, Eduardo Santos - Executive Director and Head of General Medicines, Therapeutic Areas, and Business Development | Global Value, Access, and Pricing - Amgen, Feng Liu - Executive Director | Research and Development - Regor Therapeutics, Ibrahim Turfanda - Senior Director | Next Generation Incretins | NILEX and Outcomes - Eli Lilly, Jo Bednarik - Executive Director | Medical Development, Diabetes, and Obesity - Eli Lilly, Jonathan Douros - Associate Director | Biology and Pharmacology - Novo Nordisk, Lars Johansson - Chief Scientific Officer - Antaros Medical, Leilani Morales - Global Chapter Lead | Medical Development and Evidence Generation - Roche, Maggie Kelleher - Senior Director/Team Lead | Commercial Strategy and Innovation Business Assessment | Internal Medicine and Digital - Pfizer, Manu Chakravarthy - Chief Scientific and Medical Officer - Carmot Therapeutics, Matthew Coghlan - Vice President and Head Incretin Portfolio Science - Eli Lilly, Paul Rubin - Chief Medical Officer - BioAge Labs, Scott Harris - Chief Medical Officer - Altimmune, Seulki Lee - Chief Executive Officer | D and D Pharmatech, Todd Hobbs - Chief Medical Officer - Diasome Pharmaceuticals